Remote Ischemic Conditioning for Anthracycline Cardiotoxicity: The Need to Protect the Most Vulnerable
(opens in new window)
Author(s):
Ibáñez B, Gomes-Silva M, et al.
Published in:
J Am Coll Cardiol CardioOnc, 2023, Page(s) 356-359, ISSN 2666-0873
Publisher:
NewYork: Elsevier
DOI:
10.1016/j.jaccao.2023.05.002
The quest for the mechanism responsible for the cardiovascular benefits of novel antidiabetic agents
(opens in new window)
Author(s):
Danielle Medina-Hernándeza, Carlos Galán-Arriola, and Borja Ibáñez
Published in:
REC: CardioClinics, 2023, ISSN 2605-1532
Publisher:
Elsevier
DOI:
10.1016/j.rccl.2022.09.002
Rationale and design of <scp>RESILIENCE</scp>: A prospective randomized clinical trial evaluating remote ischaemic conditioning for the prevention of anthracycline cardiotoxicity
(opens in new window)
Author(s):
Andrea Moreno‐Arciniegas, Alberto García, Malte Kelm, Francesco D'Amore, María Gomes da Silva, Javier Sánchez‐González, Pedro L. Sánchez, Teresa López‐Fernández, Raul Córdoba, Riccardo Asteggiano, Vincent Camus, Jouke Smink, Antonio Ferreira, Marie J. Kersten, Natacha Bolaños, Noemi Escalera, Elsa Pacella, Sandra Gómez‐Talavera, Antonio Quesada, Xavier Rosselló, Borja Ibanez, nu
Published in:
European Journal of Heart Failure, 2024, ISSN 1388-9842
Publisher:
Elsevier BV
DOI:
10.1002/ejhf.3395
The Quest for an Early Marker of Anthracycline-Induced Cardiotoxicity
(opens in new window)
Author(s):
Borja Ibanez, and Andrea Moreno-Arciniegas
Published in:
JACC: Basic to Translational Science, 2022, ISSN 2452-302X
Publisher:
ScienceDirect
DOI:
10.1016/j.jacbts.2021.11.010